April 14 (Reuters) - Novo Nordisk NOVOb.CO said on Monday it has become aware of several hundred units of counterfeit 1 mg dose of its diabetes drug Ozempic being distributed outside its authorized supply chain in the United States.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.